1-20 of 383
Thomas J. Kipps
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparative Analysis of Patient Characteristics, Treatment Modalities, and Survival Outcomes in Chronic Lymphocytic Leukemia from China and the US

Yuting Yan, Yin Liu, Fan Yang, Jiamei Liu, Yanfei Chen, Ying Yu, Xiong Wenjie, Tingyu Wang, Zhijian Xiao, Jianxiang Wang, Thomas J. Kipps, Robert Peter Gale, Lu-Gui Qiu, Jifang Zhou, Shuhua Yi
Journal: Blood
Blood (2024) 144 (Supplement 1): 7820.
https://doi.org/10.1182/blood-2024-204512
Published: 2024
Journal Articles

Wnt5a Enhances Chemokine-Directed Migration of T-Cells Made to Express ROR1

Daniel Elson, Christopher Seungwhan Oh, Matthew R. Cring, George F. Widhopf II, Thomas J. Kipps
Journal: Blood
Blood (2024) 144 (Supplement 1): 5761.
https://doi.org/10.1182/blood-2024-211766
Published: 2024
Journal Articles

ROR1-Signaling Increases Levels of Mutant TP53 Protein and Cyclin A1 Via Activation of NRF2, Potentially Potentiating Genomic Instability in Chronic Lymphocytic Leukemia Cells with Del(17p)

Emanuela M. Ghia, Michael Y. Choi, George F. Widhopf II, Thomas J. Kipps
Journal: Blood
Blood (2024) 144 (Supplement 1): 1852.
https://doi.org/10.1182/blood-2024-211735
Published: 2024
Journal Articles

Expression of ROR1 and ROR2 in Hairy Cell Leukemia Cells Enhances Constitutive Activation of ERK1/2 and Cancer Stemness

George F. Widhopf II, Emanuela M. Ghia, Matthew R. Cring, Thomas J. Kipps
Journal: Blood
Blood (2024) 144 (Supplement 1): 744.
https://doi.org/10.1182/blood-2024-210584
Published: 2024
Journal Articles

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study

William G. Wierda, Ryan Jacobs, Paul M Barr, John N. Allan, Tanya Siddiqi, Alessandra Tedeschi, Thomas J. Kipps, Susan M. O'Brien, Xavier C. Badoux, Andrea Visentin, Masa Lasica, Dennis A. Carney, Anna Elinder Cambrun, Javier De la Serna, Edith Szafer Glusman, Cathy Zhou, Jutta K. Neuenburg, Lynne Neumayr, Anita Szoke, James P. Dean, Paolo Ghia, Constantine S. Tam
Journal: Blood
Blood (2024) 144 (Supplement 1): 1869.
https://doi.org/10.1182/blood-2024-200936
Published: 2024
Journal Articles

The Impact of Therapeutic Selective Pressure on the Evolutionary Landscape of Chronic Lymphocytic Leukemia

Negin Karisani, Amit Sud, Liang Li, Satyen Gohil, Kristy Schlueter-Kuck, Laura Rassenti, Tuan N. Tran, Leo Wang-Kit Cheung, Iliana Edith Szafer-Glusman, James P. Dean, Guang Chen, Junko Tsuji, Neil E. Kay, Kanti R. Rai, Jennifer R. Brown, John G. Gribben, John C. Byrd, Donna S. Neuberg, Chip Stewart, Ivana Bozic, Thomas J. Kipps, Gad Getz, Catherine J. Wu
Journal: Blood
Blood (2024) 144 (Supplement 1): 3233.
https://doi.org/10.1182/blood-2024-199916
Published: 2024
Journal Articles

Lisocabtagene Maraleucel (liso-cel) Combined with Ibrutinib (ibr) for Patients (pts) with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Primary Results from the Open-Label, Phase 1/2 Transcend CLL 004 Study

William G. Wierda, Kathleen Dorritie, Jordan Gauthier, Rajneesh Nath, Thomas J. Kipps, Peter A. Riedell, Herbert A. Eradat, Saad S. Kenderian, Mohamed A. Kharfan-Dabaja, Nirav N. Shah, Scott R. Solomon, Daniel A. Ermann, Jon E. Arnason, Abhinav Deol, Tatyana Feldman, Charalambos Andreadis, Monalisa Ghosh, Shuo Ma, Stephen J. Schuster, Usama Gergis, Julie M. Vose, Jacob D. Soumerai, Koen van Besien, Sherilyn A. Tuazon, Serena K. Perna, San-San Ou, Neha Rane, Eniko Papp, Yizhe Chen, Tanya Siddiqi
Journal: Blood
Blood (2024) 144 (Supplement 1): 887.
https://doi.org/10.1182/blood-2024-200339
Published: 2024
Journal Articles

Relapse after First-Line Fixed Duration Ibrutinib + Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

Paolo Ghia, William G. Wierda, Paul M. Barr, Thomas J. Kipps, Tanya Siddiqi, John N. Allan, Zoë Hunter, Cathy Zhou, Anita Szoke, James P. Dean, Constantine S. Tam
Journal: Blood
Blood (2023) 142 (Supplement 1): 633.
https://doi.org/10.1182/blood-2023-187128
Published: 2023
Journal Articles

Comparison of Venetoclax Based Treatments for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Benjamin M. Heyman, Michael Y. Choi, Thomas J. Kipps
Journal: Blood
Blood (2023) 142 (Supplement 1): 1907.
https://doi.org/10.1182/blood-2023-188129
Published: 2023
Journal Articles

Defining Signaling Interactomes Involved in Non-Canonical Wnt Signaling By ROR1 or ROR2 in Hairy Cell Leukemia That Can Influence Cell Morphology and Migration

Matthew Cring, George Widhopf, Emanuela M. Ghia, Thomas J. Kipps
Journal: Blood
Blood (2023) 142 (Supplement 1): 4378.
https://doi.org/10.1182/blood-2023-189562
Published: 2023
Journal Articles

A Long-Term Analysis of Lenalidomide and Rituximab (R 2 ) for the Treatment of Chronic Lymphocytic Leukemia

Chung-Jiah J. Chen, Michael Y. Choi, Benjamin M. Heyman, Thomas J. Kipps
Journal: Blood
Blood (2023) 142 (Supplement 1): 4651.
https://doi.org/10.1182/blood-2023-180126
Published: 2023
Journal Articles

Combined Therapy of Zanubrutinib and Zilovertamab in the Inhibition of Invasive Capability of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, George F. Widhopf II, Thomas J. Kipps
Journal: Blood
Blood (2023) 142 (Supplement 1): 6517.
https://doi.org/10.1182/blood-2023-191114
Published: 2023
Journal Articles

Development and Testing of a Glycoengineered Anti-ROR1 Antibody with Enhanced Capacity for Directing Antibody-Dependent Cellular Cytotoxicity (ADCC) of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, George Widhopf II, Christopher Oh, Christina Girgis, Charles E. Prussak, James B. Breitmeyer, Thomas J. Kipps
Journal: Blood
Blood (2023) 142 (Supplement 1): 6836.
https://doi.org/10.1182/blood-2023-187559
Published: 2023
Journal Articles

Proteogenomic Analysis of SF3B1 mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways

Susan Klaeger, Eugen Tausch, Binyamin A. Knisbacher, Annie Apffel, Karl R Clauser, Corinne Williams, Clary Clish, Laura Z. Rassenti, Thomas J. Kipps, Kirsten Fischer, Michael Hallek, Michael A Gillette, Donna S. Neuberg, Gad Getz, DR Mani, Stephan Stilgenbauer, Catherine J. Wu, Steven A Carr
Journal: Blood
Blood (2022) 140 (Supplement 1): 9838–9839.
https://doi.org/10.1182/blood-2022-167843
Published: 2022
Journal Articles

Long-Term Analysis of Anti-CD20mab + HDMP for the Treatment of Patients with Chronic Lymphocytic Leukemia

Benjamin Heyman, Michael Y. Choi, Thomas J. Kipps
Journal: Blood
Blood (2022) 140 (Supplement 1): 12414–12415.
https://doi.org/10.1182/blood-2022-167662
Published: 2022
Journal Articles

Chemotherapy-Based Regimes Increase Karyotype Complexity of Del(11q) CLL Cells and Impact the Response to Subsequent Ibrutinib Treatment

Miguel Quijada Álamo, Laura Z. Rassenti, Emanuela M. Ghia, Tuan Tran, Monica Spydell, Elsa Molina, Claudia Pérez Carretero, Luis A. Corchete, Teresa González, Jesús María Hernández-Rivas, Thomas J. Kipps
Journal: Blood
Blood (2022) 140 (Supplement 1): 4113–4114.
https://doi.org/10.1182/blood-2022-166403
Published: 2022
Journal Articles

Rituximab and High-Dose Methylprednisolone Debulking Prior to Venetoclax for Patients with Relapsed or Refractory CLL

Michael Y. Choi, Benjamin Heyman, Minya Pu, Emily Pittman, Karen Messer, Thomas J. Kipps
Journal: Blood
Blood (2022) 140 (Supplement 1): 12410–12411.
https://doi.org/10.1182/blood-2022-170897
Published: 2022
Journal Articles

Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling

Larissa Balaian, Mary Donohoe, Phoebe Mondala, George F. Widhopf II, Emanuela M. Ghia, Edward D. Ball, Anna Kulidjian, Inge Van Der Werf, Thomas J. Kipps, Catriona Jamieson
Journal: Blood
Blood (2022) 140 (Supplement 1): 3356–3357.
https://doi.org/10.1182/blood-2022-170128
Published: 2022
Journal Articles

Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome

Erin Michelle Parry, Romain Guieze, Ignaty Leshchiner, Connor Johnson, Eugen Tausch, Sameer A. Parikh, Camilla K Lemvigh, Julien Broséus, Sébastien Hergalant, Connor Messer, Filippo Utro, Chaya Levovitz, Kahn Rhrissorrakrai, Liang Li, Shuqiang Li, Geoffrey G Fell, Robert A. Redd, Ziao Lin, Binyamin A. Knisbacher, Christof Schneider, Stacey M. Fernandes, Julian M. Hess, Laura Z. Rassenti, Thomas J. Kipps, Nitin Jain, William G. Wierda, Florence Cymbalista, Pierre Feugier, Neil E. Kay, Kenneth J Livak, Brian P Danysh, Chip Stewart, Donna S. Neuberg, Matthew S. Davids, Jennifer R. Brown, Laxmi Parida, Stephan Stilgenbauer, Gad Getz, Catherine J. Wu
Journal: Blood
Blood (2022) 140 (Supplement 1): 1530–1533.
https://doi.org/10.1182/blood-2022-160335
Published: 2022
Journal Articles

Wnt5a Induces ROR1-Dependent NFkB Activation to Upregulate MMP9 and Enhance Invasiveness in Chronic Lymphocytic Leukemia

Md Kamrul Hasan, George F. Widhopf II, Thomas J. Kipps
Journal: Blood
Blood (2022) 140 (Supplement 1): 6991.
https://doi.org/10.1182/blood-2022-170209
Published: 2022